Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.

Key facts

Study ID

NCT00020878

Run by

Jonsson Comprehensive Cancer Center

People needed

21

Starts

2001-03-01

Expected to finish

2009-05-01

Last updated by the study team

2020-08-03

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 45
• Smoked > 20 pack years

You may not qualify if…

• Concurrent use of NSAIDs
• Hypersensitivity to celecoxib
• Documented allergic-type reaction to sulfonamides
• History of allergic reaction, urticaria or asthma to aspirin or other NSAIDs
• History of liver dysfunction
• Hypertension or cardiac conditions aggravated by fluid retention and edema
• Previous history of gastrointestinal ulceration, bleeding, or perforation
• Renal dysfunction
• End stage respiratory disease
• Unstable angina
• Other malignancy
• Pregnancy
• Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes
• Patents with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.